On Monday, EuBiologics announced that it obtained regulatory approval to initiate a phase 1 study for its proprietary herpes zoster vaccine, EuHZV. With the endorsement from the Ministry of Food and Drug Safety, the company's immune modulation technology has broadened its scope from addressing emerg
Polycythemia vera (PV) is a rare, intractable blood cancer in which a somatic mutation in the bone marrow causes the bone marrow to function abnormally and overproduce red blood cells.The abnormal production of blood cells in the bone marrow causes the blood to become thick, which increases the risk
The government has nominated Noh Yun-hong, head of the Korea Pharmaceutical and Bio-Pharma Manufacturers Association (KPBMA), to chair the presidential Special Committee for Healthcare Reform.The special committee is composed of a civilian chairman, government members representing six cabinet minist
Professor Jung Mi-hyang of the Department of Cardiology at the Catholic University of Korea St. Mary's Hospital was recently appointed associate editor of the European Journal of Preventive Cardiology.The European Journal of Preventive Cardiology (IF:8.526), the official journal of the European Soci
Four Korean drugmakers have obtained approval for generic versions of Amgen's oral psoriasis treatment, Otezla (apremilast).Daewoong Pharmaceutical, DongKoo Bio&Pharma, Dong-A ST, and Chong Kun Dang will be able to enter the domestic oral psoriasis treatment market abandoned by the original drug.On
Pharmaceutical distribution company Geo-Young said Friday that its consolidated sales for 2023 reached 4.43 trillion won ($3.21 billion).It marked a 5 percent increase from the previous year’s 4.22 trillion won and the largest revenue since its inception. Operating profit for the same period rose 14
Prime Minister Han Duk-soo announced on Friday that the government would accept the request from six national university chiefs to reduce the targeted number of medical school student seats by up to 50 percent from the original 2,000.Consequently, the adjustment in medical school enrollment quotas w
The Covid-19 crisis level will be downgraded to the lowest,“attention,” of the four-tier crisis alert system next month, the government said.The Korea Disease Control and Prevention Agency (KDCA) said Friday that t after two rounds of expert consultations in January and April, most experts assessed
Bridge Biotherapeutics, a Korean biotech firm, announced positive feedback from the third Independent Data Monitoring Committee (IDMC) meeting to continue the phase 2 clinical trial of BBT-877, a drug candidate for the treatment of idiopathic pulmonary fibrosis (IPF).IPF is a severe and chronic lung
The drug price negotiations for Pfizer's third-generation ALK-positive lung cancer drug Lorviqua (lorlatinib) are being done in excessive secrecy, leading to growing frustration among patients waiting for its reimbursement.Lorviqua was not on the list of drugs that have completed drug price negotiat
The government said Thursday that it would consider including nurses as the beneficiaries of the Special Act on Handling Medical Accidents.Officials said there is no problem in including nurses in the targets of the law, citing that the draft bill, which was released in February, also stated that it
The Ministry of Food and Drug Safety has granted approval to two more digital therapeutic (DTx) devices, developed by Nunaps and Share&Service. These devices, which are the third and fourth authorized DTx in the country, utilize software to assist in cognitive improvement and respiratory rehabilitat
3Bigs, a Korean company specializing in bio big data-based health management solutions, said it entered a distribution partnership with Neo-Science, a bio-health enterprise located in Abu Dhabi, the UAE.Under the accord, Neo-Science will manage the sales of several key 3Bigs products, including the
The International Kidney Cancer Coalition (IKCC)’s International Conference 2024 wrapped up its three-day event in Incheon, Korea, on Tuesday. About 60 kidney cancer patient group leaders from 21 countries, medical doctors, and university professors attended.Korea is the first Asian country to host
Koreans with neuroendocrine tumors have been forced to leave for overseas treatment due to the restriction on the number of domestic treatments -- four reimbursed and two non-reimbursed treatments -- using Lutathera (lutetium oxodotreotide), a radiopharmaceutical treatment.After persistent advocacy,
HLB said it opened a new office in the Cambridge Innovation Center (CIC) in Boston, U.S. to bolster the collaboration and communication between HLB and its U.S. subsidiaries, such as Immunomic Therapeutics, while also supporting its group companies' entry into international markets.HLB's new office
The International Nonproprietary Name (INN) of LAPS Glucagon analog (code name HM15136), which Hanmi Pharm is developing as an innovative new drug for treating congenital hyperinsulinemia, has been fixed as “efpegerglucagon.”Hanmi Pharm said Thursday that the World Health Organization has officially
SK biopharmaceuticals said Thursday it has signed a technology transfer agreement with a Chinese joint venture company, Ignis Therapeutics, for a non-narcotic pain treatment candidate worth 80.4 billion won ($58 million).Under the agreement, SK biopharmaceuticals will transfer the global development
Handok and Swedish Orphan Biovitrum (Sobi) said they have officially inaugurated their Korean joint venture, Handok-Sobi.Sobi is a global biopharmaceutical company specializing in rare diseases, providing innovative treatments in hematology, immunology, and specialized therapies. With 1,800 employee
GC Cell said its U.S. affiliate Artiva Biotherapeutics has begun administering the first dose to a participant in a phase 1 clinical trial. This trial investigates the combination of AlloNK (AB-101) and rituximab as a potential treatment for lupus nephritis.Lupus nephritis is a complication of syste